Guillain-Barre Syndrome - Pipeline Review, H2 2020
Guillain-Barre Syndrome - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Pipeline Review, H2 2020, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape.
Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrical weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until certain muscles cannot be used at all and, when severe, the person is almost totally paralyzed. Risk Factors include influenza virus, mycoplasma pneumonia, Hodgkin's lymphoma and Epstein-Barr virus.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Guillain-Barre Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Guillain-Barre Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Guillain-Barre Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed and Preclinical stages are 3, 1 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Guillain-Barre Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Pipeline Review, H2 2020, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape.
Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrical weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until certain muscles cannot be used at all and, when severe, the person is almost totally paralyzed. Risk Factors include influenza virus, mycoplasma pneumonia, Hodgkin's lymphoma and Epstein-Barr virus.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Guillain-Barre Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Guillain-Barre Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Guillain-Barre Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed and Preclinical stages are 3, 1 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Guillain-Barre Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Guillain-Barre Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Guillain-Barre Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Guillain-Barre Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Guillain-Barre Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Guillain-Barre Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Guillain-Barre Syndrome - Overview
Guillain-Barre Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Guillain-Barre Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Guillain-Barre Syndrome - Companies Involved in Therapeutics Development
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Annexon Inc
Cellenkos Inc
Complement Pharma BV
CuraVac Inc
Hansa Biopharma AB
Polyneuron Pharmaceuticals AG
Vitality Biopharma Inc
Guillain-Barre Syndrome - Drug Profiles
ANX-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CK-0801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CP-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imlifidase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nomacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PN-1018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Guillain-Barre Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Guillain-Barre Syndrome - Dormant Projects
Guillain-Barre Syndrome - Product Development Milestones
Featured News & Press Releases
Apr 15, 2019: Hansa Biopharma receives ethics and regulatory clearance to start Phase 2 study of imlifidase in Guillain Barr? Syndrome
Feb 16, 2018: Hansa Medical receives FDA Orphan Drug Designation for IdeS and the treatment of Guillain-Barre syndrome
Feb 16, 2017: Novel pre-clinical in vivo data demonstrate the treatment potential of IdeS in Guillain-Barre syndrome
May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barr? Syndrome
May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain Barr? Syndrome
Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial
Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays
Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Figures
Introduction
Global Markets Direct Report Coverage
Guillain-Barre Syndrome - Overview
Guillain-Barre Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Guillain-Barre Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Guillain-Barre Syndrome - Companies Involved in Therapeutics Development
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Annexon Inc
Cellenkos Inc
Complement Pharma BV
CuraVac Inc
Hansa Biopharma AB
Polyneuron Pharmaceuticals AG
Vitality Biopharma Inc
Guillain-Barre Syndrome - Drug Profiles
ANX-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CK-0801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CP-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imlifidase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nomacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PN-1018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Guillain-Barre Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Guillain-Barre Syndrome - Dormant Projects
Guillain-Barre Syndrome - Product Development Milestones
Featured News & Press Releases
Apr 15, 2019: Hansa Biopharma receives ethics and regulatory clearance to start Phase 2 study of imlifidase in Guillain Barr? Syndrome
Feb 16, 2018: Hansa Medical receives FDA Orphan Drug Designation for IdeS and the treatment of Guillain-Barre syndrome
Feb 16, 2017: Novel pre-clinical in vivo data demonstrate the treatment potential of IdeS in Guillain-Barre syndrome
May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barr? Syndrome
May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain Barr? Syndrome
Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial
Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays
Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Guillain-Barre Syndrome, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Guillain-Barre Syndrome - Pipeline by Akari Therapeutics Plc, H2 2020
Guillain-Barre Syndrome - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
Guillain-Barre Syndrome - Pipeline by Annexon Inc, H2 2020
Guillain-Barre Syndrome - Pipeline by Cellenkos Inc, H2 2020
Guillain-Barre Syndrome - Pipeline by Complement Pharma BV, H2 2020
Guillain-Barre Syndrome - Pipeline by CuraVac Inc, H2 2020
Guillain-Barre Syndrome - Pipeline by Hansa Biopharma AB, H2 2020
Guillain-Barre Syndrome - Pipeline by Polyneuron Pharmaceuticals AG, H2 2020
Guillain-Barre Syndrome - Pipeline by Vitality Biopharma Inc, H2 2020
Guillain-Barre Syndrome - Dormant Projects, H2 2020
Number of Products under Development for Guillain-Barre Syndrome, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Guillain-Barre Syndrome - Pipeline by Akari Therapeutics Plc, H2 2020
Guillain-Barre Syndrome - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
Guillain-Barre Syndrome - Pipeline by Annexon Inc, H2 2020
Guillain-Barre Syndrome - Pipeline by Cellenkos Inc, H2 2020
Guillain-Barre Syndrome - Pipeline by Complement Pharma BV, H2 2020
Guillain-Barre Syndrome - Pipeline by CuraVac Inc, H2 2020
Guillain-Barre Syndrome - Pipeline by Hansa Biopharma AB, H2 2020
Guillain-Barre Syndrome - Pipeline by Polyneuron Pharmaceuticals AG, H2 2020
Guillain-Barre Syndrome - Pipeline by Vitality Biopharma Inc, H2 2020
Guillain-Barre Syndrome - Dormant Projects, H2 2020
LIST OF FIGURES
Number of Products under Development for Guillain-Barre Syndrome, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
Number of Products under Development for Guillain-Barre Syndrome, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
